Proton pump inhibitor therapy for chronic laryngo-pharyngitis: a randomized placebo-control trial

Otolaryngol Head Neck Surg. 2004 Oct;131(4):342-50. doi: 10.1016/j.otohns.2004.03.037.

Abstract

Objective: To determine the efficacy of proton-pump inhibitor (PPI) therapy for chronic laryngo-pharyngitis treated with lifestyle modification.

Study design and methods: Double-blind, randomized trial comparing two-month Rabeprazole (20 mg b.i.d.) to placebo control.

Results: Compared to baseline, both PPI and control patients had significant improvement in total reflux symptoms (P = 0.002 and P = 0.03 respectively), with significant improvement in "laryngo-pharyngeal" but not "typical" reflux symptoms. No significant difference was noted for change in reflux symptoms between PPI-treated and control patients (P = 0.44). Significant global improvement was noted by 50% of control and 53% of PPI-treated patients (P = 1.0). No significant differences were noted within or between treatment groups for change in health status or videostrobolaryngoscopy grade. Lifestyle modification compliance correlated significantly with global improvement.

Conclusion: Compared to baseline, lifestyle modification for 2 months significantly improved chronic laryngo-pharyngitis symptoms. When compared to control, treatment with a PPI failed to demonstrate significantly greater improvement in reflux symptoms, health status, or laryngeal appearance.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Benzimidazoles / therapeutic use*
  • Chronic Disease
  • Double-Blind Method
  • Enzyme Inhibitors / therapeutic use*
  • Female
  • Gastroesophageal Reflux / complications
  • Gastroesophageal Reflux / drug therapy
  • Humans
  • Hypopharynx*
  • Life Style
  • Male
  • Middle Aged
  • Omeprazole / analogs & derivatives
  • Pharyngitis / drug therapy*
  • Pharyngitis / etiology
  • Proton Pump Inhibitors*
  • Rabeprazole
  • Treatment Outcome

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Benzimidazoles
  • Enzyme Inhibitors
  • Proton Pump Inhibitors
  • Rabeprazole
  • Omeprazole